1316216-05-3

Basic information

• Product Name: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate
• Synonyms: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate
• CAS NO: 1316216-05-3
• Molecular Formula: C₁₉H₁₇N₃O₂
• Molecular Weight: 319.35718
• Mol File: 1316216-05-3.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(1316216-05-3)
• EPA Substance Registry System: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(1316216-05-3)

Safety Data

• Hazardous Substances Data: 1316216-05-3(Hazardous Substances Data)

Upstream product

• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 62-53-3 aniline 
• 591-50-4 iodobenzene 
• 864172-93-0 ethyl 2-(phenylamino)pyrimidine-5-carboxylate 
• 95928-49-7 2-hydroxy-pyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 1316216-07-5 C₂₅H₂₈N₄O₃ 
• 1316214-52-4 N-[7-(hydroxyamino)-7-oxo-heptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide 
• 1316216-06-4 C₁₇H₁₃N₃O₂ 

Relevant articles and documents

Mercapto compounds as histone deacetylase inhibitors and uses thereof

Experimental results show, that the compound shown by the invention has high blood-brain barrier permeability, on normal cytotoxic low, potential cardiac toxicity, and higher blood-brain barrier permeability of, on a cell model as a compound shown, or a pharmaceutically acceptable salt, ester or a prodrug, of the compound as a high-efficiency low-toxicity anti-tumor or neurodegenerative disease therapeutic agent shown in the invention. The compound has high blood-brain barrier permeability . The compound of the present invention has higher blood-brain barrier permeability as shown in the development prospect (I) of, a: therapeutic agent for high-efficiency and low-toxicity antitumor or neurodegenerative diseases.

METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES

The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treatin

PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.